Rated high-performing in prostate cancer surgery.
A new Phase 2 trial at UC Davis Comprehensive Cancer Center is evaluating the PARP inhibitor niraparib as a neoadjuvant therapy for men with high-risk, localized prostate cancer. The study focuses on patients with DNA repair gene mutations, including germline variants in BRCA2, MSH6, CHEK2 and somatic alterations in ATM, SPOP, KMT2C, KMT2D, among others.
Two urologic oncologists have recently joined the UC Davis Comprehensive Cancer Center, expanding the center’
Urologic surgeon Thenappan Chandrasekar and UC Davis Comprehensive Cancer Center researchers are offering a new groundbreaking clinical trial for bladder cancer patients. Previously, about 70% of these patients could only “watch and wait” and hope their cancer did not return.
We welcome the opportunity to partner with you in caring for your patient.
Our specialists are available when the need arises. Learn more about a specific health specialty.
The goal of clinical studies at UC Davis Health is to discover and share knowledge to advance health.
A U.S. News & World Report best hospital in cardiology, heart & vascular surgery, diabetes & endocrinology, ENT, geriatrics, neurology & neurosurgery, and pulmonology & lung surgery.
U.S. News & World Report rated UC Davis Medical Center high-performing in prostate cancer surgery.
One of ~59 U.S. cancer centers designated “comprehensive” by the National Cancer Institute.
UC Davis Medical Center has received Magnet® recognition, the nation’s highest honor for nursing excellence.
Ranked Sacramento’s #1 hospital by U.S. News, and high-performing in aortic valve surgery, back surgery (spinal fusion), COPD, colon cancer surgery, diabetes, gynecological cancer surgery, heart arrhythmia, heart failure, kidney failure, leukemia, lymphoma & myeloma, lung cancer surgery, pacemaker implantation, pneumonia, prostate cancer surgery, stroke, TAVR, cancer, orthopedics, gastroenterology & GI surgery, and urology.